Myriad Genetics Cut to Underweight as Piper Questions Path to Profit
Piper Sandler double-downgraded MYGN, saying the current model cannot grow or cut its way to profit.
Already have an account? Sign in.
Piper Sandler double-downgraded MYGN, saying the current model cannot grow or cut its way to profit.
The FDA approved Scholar Rock’s Isembyld, the first SMA therapy aimed at muscle wasting in patients already on nerve-targeted treatment.
The Phase III SERENA-4 trial did not meet its primary PFS endpoint in untreated advanced ER-positive, HER2-negative breast cancer, despite a numerical benefit.
Citi added a 90-day upside view on AppLovin with a $600 target, calling Q3 concerns misguided.